LYRA vs NIVF

LYRA is in a state of severe financial distress, evidenced by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.25, indicating negative shareholder equity. The company has experienced a catastrophic revenue collapse of -96.70% YoY and an extreme operating margin of -98,728.57%. With a 52-week high of $37.50 now trading at $0.65, the stock has lost nearly all its value. The combination of negative equity, vanishing revenue, and bearish insider activity suggests a high risk of insolvency.

NIVF exhibits a catastrophic price collapse (-99.8% over 1 year) and severe operational dysfunction. While the Piotroski F-Score of 5/9 suggests baseline stability, this is heavily skewed by a non-operating profit spike, as evidenced by a 209.03% profit margin contrasted against a disastrous -349.13% operating margin. The company is fundamentally unable to generate profit from its core medical care facilities. The massive discrepancy between the current price ($2.19) and the single analyst's target price ($900) indicates a complete breakdown in valuation reliability.